| Analysis of the coding genome of diffuse large B-cell lymphoma L Pasqualucci, V Trifonov, G Fabbri, J Ma, D Rossi, A Chiarenza, ... Nature genetics 43 (9), 830-837, 2011 | 1144 | 2011 |
| Inactivating mutations of acetyltransferase genes in B-cell lymphoma L Pasqualucci, D Dominguez-Sola, A Chiarenza, G Fabbri, A Grunn, ... Nature 471 (7337), 189-195, 2011 | 1059 | 2011 |
| Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation G Fabbri, S Rasi, D Rossi, V Trifonov, H Khiabanian, J Ma, A Grunn, ... Journal of Experimental Medicine 208 (7), 1389-1401, 2011 | 791 | 2011 |
| Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, C Ciardullo, ... Blood, The Journal of the American Society of Hematology 121 (8), 1403-1412, 2013 | 605 | 2013 |
| Genetics of follicular lymphoma transformation L Pasqualucci, H Khiabanian, M Fangazio, M Vasishtha, M Messina, ... Cell reports 6 (1), 130-140, 2014 | 599 | 2014 |
| Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia D Rossi, S Rasi, G Fabbri, V Spina, M Fangazio, F Forconi, R Marasca, ... Blood, The Journal of the American Society of Hematology 119 (2), 521-529, 2012 | 558 | 2012 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria, M Offidani, ... Journal of Clinical Oncology 28 (34), 5101-5109, 2010 | 520 | 2010 |
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients S Bringhen, A Larocca, D Rossi, M Cavalli, M Genuardi, R Ria, S Gentili, ... Blood, The Journal of the American Society of Hematology 116 (23), 4745-4753, 2010 | 498 | 2010 |
| Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness D Rossi, A Bruscaggin, V Spina, S Rasi, H Khiabanian, M Messina, ... Blood, The Journal of the American Society of Hematology 118 (26), 6904-6908, 2011 | 490 | 2011 |
| Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma R Crescenzo, F Abate, E Lasorsa, M Gaudiano, N Chiesa, F Di Giacomo, ... Cancer cell 27 (4), 516-532, 2015 | 444 | 2015 |
| The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ... Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011 | 426 | 2011 |
| The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development D Rossi, V Trifonov, M Fangazio, A Bruscaggin, S Rasi, V Spina, S Monti, ... Journal of Experimental Medicine 209 (9), 1537-1551, 2012 | 424 | 2012 |
| Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia D Rossi, H Khiabanian, V Spina, C Ciardullo, A Bruscaggin, R Famà, ... Blood, The Journal of the American Society of Hematology 123 (14), 2139-2147, 2014 | 420 | 2014 |
| Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study A Bhangu, AO Ademuyiwa, ML Aguilera, P Alexander, SW Al-Saqqa, ... The Lancet Infectious Diseases 18 (5), 516-525, 2018 | 415 | 2018 |
| The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness D Rossi, M Cerri, C Deambrogi, E Sozzi, S Cresta, S Rasi, L De Paoli, ... Clinical cancer research 15 (3), 995-1004, 2009 | 411 | 2009 |
| Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia D Rossi, M Fangazio, S Rasi, T Vaisitti, S Monti, S Cresta, S Chiaretti, ... Blood, The Journal of the American Society of Hematology 119 (12), 2854-2862, 2012 | 395 | 2012 |
| Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial A Palumbo, M Cavo, S Bringhen, E Zamagni, A Romano, F Patriarca, ... Journal of Clinical Oncology 29 (8), 986-993, 2011 | 395 | 2011 |
| Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma DM Kurtz, F Scherer, MC Jin, J Soo, AFM Craig, MS Esfahani, JJ Chabon, ... Journal of Clinical Oncology 36 (28), 2845, 2018 | 392 | 2018 |
| Recurrent mutations refine prognosis in chronic lymphocytic leukemia P Baliakas, A Hadzidimitriou, LA Sutton, D Rossi, E Minga, N Villamor, ... Leukemia 29 (2), 329-336, 2015 | 383 | 2015 |
| Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma M Esteller, G Gaidano, SN Goodman, V Zagonel, D Capello, B Botto, ... Journal of the National Cancer Institute 94 (1), 26-32, 2002 | 359 | 2002 |
